BioAtla, Inc.
BCAB- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826892
No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding BioAtla, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 73 | 91 | +18 |
| Shares | 24.9M | 33.8M | +8.98M (+36.1%) |
| Value | $191.5M | $279.2M | +$87.7M (+45.8%) |
New holders (29)
Institutions that held BioAtla, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (11)
Institutions that held BioAtla, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Healthcare of Ontario Pension Plan Trust Fund | 860,200 | $6.62M |
| Eventide Asset Management, LLC | 795,000 | $6.12M |
| Avoro Capital Advisors LLC | 575,000 | $4.43M |
| Altium Capital Management LP | 553,000 | $4.26M |
| UBS Oconnor LLC | 112,000 | $862.0K |
| Occudo Quantitative Strategies LP | 19,885 | $153.0K |
| BNP Paribas Arbitrage, SA | 16,279 | $125.3K |
| Schonfeld Strategic Advisors LLC | 14,900 | $115.0K |
| DekaBank Deutsche Girozentrale | 12,500 | $95.0K |
| Point72 Hong Kong Ltd | 421 | $3.00K |
| Advisor Group Holdings, Inc. | 50 | $0 |